abstract |
An IgG1-type anti-huTNFR1 antibody and a pharmaceutical used as a TNF antagonist are provided. An IgG1-type anti-huTNFR1 antibody having a modified Fc region that is deficient in Fc-mediated effector functions, pharmaceuticals containing such antibodies, and agonists as an alternative to treatment with anti-TNF therapeutics The present invention relates to an IgG1-type anti-huTNFR1 antibody used as a TNF antagonist without forming a TNFR1 signaling complex. [Selection figure] None |